Get the StoQuant digest — free

Free StoQuant digest by email. No account needed. See today's research picks.

Subscribe free

DMRA vs IMCR — Stock Comparison

Compare DMRA and IMCR side-by-side on StoQuant: DMRA Q-Score 50 vs IMCR 52; analyst signal 80 vs 71. Plus alt data signals, insider buying, catalysts, strategic edges, short interest, social sentiment, and macro context.

Side-by-side snapshot

• DMRA — Galecto, Inc. · Health Care · market cap $1.30B · Q-Score verdict Unrated (50.0) · analyst signal 80/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: analyst consensus 91/100, valuation 43/100 · weakest signals: technicals 32/100, competitive moat 2/100. Full DMRA research.
• IMCR — Immunocore Holdings plc · Health Care · market cap $1.60B · Q-Score verdict Hold (52.0, grade C) · analyst signal 71/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: competitive moat 86/100, valuation 79/100 · weakest signals: analyst consensus 60/100, technicals 52/100. Full IMCR research.

What you can compare

• Q-Score: StoQuant's composite 0–100 rating based on 140+ financial signals.
• Alt data signals: Google Trends, EDGAR 8-K filings, job postings, and more.
• Insider activity: Cluster scores and recent Form 4 buying.
• Catalysts: Earnings, analyst changes, M&A, clinical trials, and SEC events.
• Strategic edges: Competitive moat and durable advantage analysis.
• Short interest & social sentiment: Short % float, social mention volume, and bullish/bearish breakdown.
• Macro context: Market regime and sector rotation alignment.

Deep dive: DMRA research · IMCR research. Sign in to StoQuant to run live comparisons for any tickers. Sign up free →